Concepedia

Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer

Leonardo Mirandola, Yuefei Yu, Martin J. Cannon, Marjorie Jenkins, Rakhshanda Layeequr Rahman, Diane Nguyen, Fabio Grizzi, Everardo Cobos, José A. Figueroa, Maurizio Chiriva‐Internati

Gynecologic Oncology · 2014 · 49 citations · 30 references

DOI

Concepts

References

30

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Robert A. Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine · 2011 · 2.4K citations · Full text

, , +11

The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory

Robert J. Kurman, Ie‐Ming Shih · The American Journal of Surgical Pathology · 2010 · 1.8K citations · Full text

, , +17

Ovarian cancer

Bryan T. Hennessy, Robert L. Coleman, Maurie Markman · The Lancet · 2009 · 652 citations

EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer

Alexandria Haslehurst, Madhuri Koti, Moyez Dharsee et al. · BMC Cancer · 2012 · 405 citations · Full text

, , +17

Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response

Anna Markowska, Fu‐Tong Liu, Noorjahan Panjwani · The Journal of Experimental Medicine · 2010 · 328 citations · Full text

, , +14